NDA 204114/S-036
NDA 217513/S-010

CORRECTION – SUPPLEMENT APPROVAL/ FULFILLMENT OF POSTMARKETING COMMITMENT

Novartis Pharmaceuticals Corporation
Attention: Victoria Papademas, PharmD
Global Program Regulatory Director
One Health Plaza
East Hanover, NJ 07936-1080

Dear Dr. Papademas:

Please refer to your supplemental new drug application (sNDA) dated and received August 1, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Mekinist (trametinib) tablets.

We also refer to your sNDA dated and received September 20, 2024, and your amendments, submitted under section 505(b) of the FDCA for Mekinist (trametinib) for oral solution, which cross-references to the August 1, 2024, sNDA noted above.

We also refer to our sNDA Approval letter dated January 24, 2025, which contained an incorrect final U.S. Prescribing Information (USPI) labeling for Mekinist. Specifically, this corrected action letter incorporates accurate companion diagnostic information for the anaplastic thyroid cancer and low-grade glioma indications in the Dosage and Administration section of the USPI. The effective action date will remain January 24, 2025, the date of the original letter.

These prior approval sNDAs provide updates to the Mekinist (trametinib) USPI labeling to include the availability of an FDA-approved companion diagnostic for the identification of BRAF V600E mutations in the anaplastic thyroid cancer indication, in addition to fulfillment of Postmarketing Commitment 3378-2 under NDA 204114.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Instructions for Use), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

Requirement.

FULFILLMENT OF POSTMARKETING COMMITMENT

We have received your submission dated July 14, 2021, containing the final report for the following postmarketing commitment listed in the May 4, 2018, approval letter.

3378-2 Commitment to establish, through the use of clinical trial data, an in-vitro diagnostic device that is essential to the safe and effective use of dabrafenib and trametinib for patients with BRAF V600E mutations in anaplastic thyroid cancer (ATC) tumor specimens.

We have reviewed your submission and conclude that the above commitment was fulfilled.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our May 4, 2018, letter. You are not required to report on the status of closed (released or fulfilled) PMRs/PMC in your annual report required under 21 CFR 314.81(b)(2)(vii) of the FD&CA.

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Raniya Al-Matari, Regulatory Health Project Manager, at 301-796-1755 or Raniya.Al-Matari@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Nicole Drezner, M.D.
Deputy Director
Division of Oncology 2
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
  - Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NICOLE L DREZNER
02/12/2025 01:07:40 PM